Clinical Trial Update: Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safinamide for levodopa-induced dyskinesia in Parkinson's disease subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED